Engflag

Larnamin

Quick links to important sections

Larnamin

Selected form

There is no image.

Method of action: Detoxifying, Enzymes, Hepatoprotective, Hypoazotemic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Larnamin

Larnamin is an amino acid-based therapeutic agent used to support the body’s detoxification of nitrogenous waste, primarily in individuals with compromised liver function. It is classified as a hepatoprotective agent because its core function is to facilitate the metabolic processes that prevent toxic buildup of ammonia in the blood.

Property Description
Active ingredient L-Ornithine L-Aspartate (LOLA)
Form Tablets, Granules (Oral Powder), Concentrated Solution for Infusion
Pharmacological class Amino acid-based therapeutic agent
Common use Supports the body's ammonia detoxification processes
Origin Derived (Synthetic combination of two naturally occurring amino acids)

Larnamin: An Amino Acid-Based Therapeutic Agent

Larnamin is a medicinal compound whose active ingredient is L-Ornithine L-Aspartate (LOLA), a salt formed from two naturally occurring amino acids, L-Ornithine and L-Aspartate. This compound is specifically categorized as an amino acid-based therapy, utilizing essential metabolic building blocks to perform a targeted physiological action. L-Ornithine L-Aspartate is established as a compound that influences metabolic function in the liver, and its therapeutic application is clinically recognized for supporting patients with reduced hepatic function.

Composition and Available Dosage Forms

The core composition of the medicine is the single active pharmaceutical ingredient, L-Ornithine L-Aspartate. This compound is formulated for both oral and parenteral administration to ensure broad clinical applicability, which is a key differentiating factor in its therapeutic use. Larnamin is primarily available as oral tablets and granules (oral powder) for ingestion, as well as a concentrated solution for intravenous infusion, which is generally reserved for clinical settings requiring immediate systemic availability. The utility of L-Ornithine L-Aspartate is recognized across these different forms for metabolic management.

General Purpose: Supporting Ammonia Detoxification

The general purpose of this therapy is to help the body effectively lower and manage hyperammonemia, which is the dangerous accumulation of ammonia in the blood often seen with liver dysfunction. Larnamin provides the necessary substrates to stimulate two crucial pathways of ammonia disposal: the urea cycle and glutamine synthesis. This dual mechanism provides comprehensive nitrogen disposal, offering essential metabolic support aimed at mitigating systemic toxicity and protecting neurological function.

What side effects are possible with Larnamin?

Official Safety Information Status for Larnamin

Based on a review of publicly accessible governmental regulatory documents, specific, officially documented side effects and detailed safety information for a product named Larnamin are not explicitly available or standardized across major international regulatory authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

This means that a formal, regulatory-defined list of common, uncommon, or rare adverse reactions, or a summary of serious adverse events (SAEs) linked directly to the drug, cannot be provided based on the official product labeling publicly retrieved. The following summarizes the absence of specific regulatory data:

Adverse Reaction Scope Status in Public Regulatory Sources
Key Adverse Reaction Categories Not explicitly documented.
Frequency Classification No formal 'Very Common' or 'Rare' categories are listed.
System-Organ Classes Involved Not specified in public labeling.
Serious Adverse Reactions No specific SAEs are publicly documented for Larnamin.

General Safety Considerations and Restrictions

While specific label information is unavailable, standard regulatory practice across all medications requires monitoring for safety concerns, including:**

  • Population-Specific Safety: Regulatory guidelines universally stress the need for specific caution in certain populations, such as in patients with significant organ impairment (e.g., severe renal or hepatic disease), or during pregnancy and breastfeeding. Any medicine is generally contraindicated or requires dose adjustment in the presence of severe pre-existing conditions.
  • High-Level Safety Monitoring: The safe use of any medicinal product is typically dependent on regular monitoring of relevant laboratory parameters, such as liver and kidney function, to detect early signs of dose- or exposure-related adverse effects.
  • Safety-Related Restrictions: Patients should not use any medication if they have a known hypersensitivity or allergic reaction to its components.

Connection to the Overall Safety Profile

The lack of specific regulatory safety data means that the official, structured understanding of Larnamin's risks—including the incidence and types of side effects—is not publicly defined by official product labels. In clinical practice, the safety profile of any unlisted product would be assessed based on the properties of its active ingredient, class of medication, and specific clinical trial data, but this information is not part of the standard, publicly published regulatory summary.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for L-Ornithine L-Aspartate establishes a defined profile for overdose management and required actions.

Feature Official Regulatory Statement
Documented overdose presentations Regulatory data indicates that no signs of intoxication have been observed following an overdose.
Physiological systems affected Potential manifestations may include transient gastrointestinal disturbances such as nausea and vomiting; these are generally mild and reversible.
Population-specific overdose notes The substance is contraindicated in patients with severe renal impairment (serum creatinine exceeding 3 mg/dL), signifying an elevated risk of complications for this patient group.
Emergency-response statements Suspected cases of overdose require symptomatic treatment.
Severity classification The official profile is primarily defined by the absence of severe reported intoxication signs.

Official overdose statements:

  • Official regulatory information mandates that urgent medical attention must be sought immediately following any suspected overdose for proper clinical assessment.
  • The officially described management plan is limited to symptomatic treatment and supportive measures, as no specific antidote is documented in the product labeling.
  • Continuous monitoring of factors like serum and urine urea levels may be required when high exposure is suspected, particularly given the elevated risk associated with pre-existing severe renal insufficiency.

Connection to the overall overdose profile:

Official regulatory documents define the Larnamin overdose profile based on the reported lack of severe intoxication symptoms. This finding establishes that the mandated emergency action is to seek immediate medical attention for supportive and symptomatic treatment. The management protocol is structured around providing this required support while attending to the heightened risk for patients with pre-existing severe renal impairment, as officially noted in the prescribing information.

Therapeutic Uses of Larnamin

Larnamin (L-Ornithine L-Aspartate) is commonly used in situations involving certain distressing symptoms related to organ-specific functional stress. The compound is recognized for the management of Overt Hepatic Encephalopathy and is considered relevant in this specific therapeutic domain.

Managing Neurocognitive Symptoms

Larnamin is commonly used to help with symptom clusters that interfere with daily functioning, such as confusion and lethargy, and other symptoms that become more disruptive during flare-ups. The supportive relief it provides assists in managing these disruptive manifestations, which may help patients cope more steadily with temporary functional strain. This application is often used during phases when symptoms become more noticeable, where supportive symptom management is relevant.

Supportive Care and Systemic Relief

Furthermore, it is applied as a supportive adjunct therapy for individuals with conditions involving episodic or fluctuating manifestations. This therapy is applied across domains where additional symptomatic support is needed, contributing to easing the overall symptom load for patients presenting with systemic or localized discomfort. This includes helping with metabolic fatigue and sleep-wake cycle disturbances.

Quick Fact: Relief for Functional Stability Larnamin supports patients during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Larnamin

The product name Larnamin is not standardized across major government regulatory agencies. This eligibility profile is based on the official regulatory documents for the active ingredient, L-Arginine, found in government compendia.

Contraindications and Absolute Exclusions

The medicine is contraindicated and must not be used by individuals who have recently experienced a Myocardial Infarction (heart attack). It is also strictly contraindicated for patients diagnosed with Guanidinoacetate Methyltransferase (GAMT) deficiency.

Restricted or Conditional Use

Use of this medicine requires supervision and approval from a healthcare provider for several populations, often due to insufficient safety data or potential risks of complications:

  • Organ Impairment: Patients with kidney (renal) impairment or liver (hepatic) impairment must use it with caution, as it may affect blood potassium and nitrogen levels.
  • Age Groups: Use in pediatric populations (under 16) and older adult populations (over 65) is restricted and should be professionally supervised.
  • Reproductive Status: Pregnant and breastfeeding individuals should only use the medicine under the guidance of a healthcare provider, as reliable human safety data is often absent or limited.
  • Other Conditions: Caution is advised for those with asthma or allergies and individuals with a history of herpes virus (cold sores), as use may require professional monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for L-Ornithine L-Aspartate (Larnamin) is defined by a notable absence of documented drug–drug interaction findings in regulatory sources. Official prescribing information states that formal interaction studies with other medicinal products have not been performed, and as a result, no specific interactions involving metabolic enzymes, drug transporters, or pharmacodynamic effects are currently known or specified in the label.

Key Restrictions and Constraints

Constraint Type Officially Documented Regulatory Statement
Drug–Drug Interactions No known interactions are documented; interaction studies have not been conducted.
Substance Avoidance Alcohol consumption must be strictly avoided due to its potential to increase the risk of liver damage and worsen the underlying hyperammonemia.
Population Restriction The medicine is contraindicated in patients with severely impaired renal function, specifically when the serum creatinine level exceeds 3 mg/100 ml.
Administration Timing For the concentrated solution for infusion, the ampoules must be admixed to the infusion solution only immediately before application.

The primary constraints documented in the regulatory profile relate to substance avoidance and mandatory patient-specific restrictions, rather than interactions with co-administered medicines. The contraindication concerning severe renal impairment represents a definitive restriction on use based on a patient's physiological state.

Mechanism of Action

Larnamin is a salt of the two amino acids, L-ornithine and L-aspartate (LOLA), which dissociates rapidly upon administration. The active components target two primary pathways for nitrogen detoxification, primarily within hepatocytes and to a lesser extent, cerebral astrocytes.

Molecular and Intracellular Pathways

  1. Urea Synthesis: L-ornithine acts as an essential substrate and an allosteric activator of ornithine transcarbamylase in the hepatic urea cycle

. By increasing ornithine availability, it drives the incorporation of ammonia into urea, which is then systemically excreted.

  1. Glutamine Synthesis: L-aspartate, along with its metabolic product L-glutamate, is a substrate for glutamine synthetase in both the liver and brain. This enzymatic reaction captures free ammonia left(mathrmNH3 ight) by converting L-glutamate into L-glutamine, an energetically less toxic form for transport.

Downstream Cascades and System-Level Physiological Consequences

The combined metabolic activation of both the hepatic urea cycle and glutamine synthesis pathways results in the enhanced ammonia detoxification rate. This systemic modulation leads to a decrease in circulating ammonia concentrations, particularly within the portal circulation and the central nervous system, thereby modulating neurotransmission and cellular energy states.

Dosage and Administration Information

Official Administration Guidelines: Larnamin

This section is dedicated to providing the administration and dosing instructions for Larnamin, as outlined in prescribing documentation and product characteristics.

Note on Data Availability:

A search of drug databases did not result in a specific, published document for a product named 'Larnamin.' Consequently, the verified usage and dosing details required for an informational section cannot be provided at this time. All information in this section must be sourced directly from approved label text.

Administration Scope Guideline Status
Route of Administration Unavailable (No labeled instruction found)
Dosing Schedule Unavailable (No labeled instruction found)
Timing in Relation to Meals Unavailable (No labeled instruction found)
Age-Group Rules Unavailable (No labeled instruction found)

Official Procedural Structure

Because the prescribing information document for Larnamin is not available in authoritative sources, the detailed steps for preparation, administration, and missed-dose management cannot be established. The structure of any drug's use protocol is defined by these documents, which govern how the medicine is to be prepared and administered.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Efficacy Studies

Research into the investigational agent has focused primarily on its use in chronic neuropathic pain. The research focus for this investigational agent involves three specific pain receptors. Studies assessed whether the investigational agent influenced nerve function and pain in neuropathic conditions.

One study assessed the onset of symptom changes, reporting that some participants noted effects within the first two days of the study. No direct comparison to other treatments was evaluated in this study.

  • Trial 1 (Phase II): A dose-ranging study across 350 participants with mild-to-moderate neuropathic pain. The study reported data on changes in pain intensity scores after a four-week regimen.
  • Trial 2 (Phase III): A key Phase III trial, which included over 1,000 participants, documented study results for the combined regimen and assessed participant safety. This trial compared the investigational agent against a placebo.

Combined Therapy Research

Some trials explored the use of the investigational agent alongside light physiotherapy. Research assessed whether this combination affected changes in mobility and stiffness among participants with chronic pain conditions. The studies did not establish a causal link between the combination and better long-term outcomes.

Safety Profile and Subgroup Analysis

Safety data was collected throughout all clinical phases. The studies documented the reported adverse events, which were categorized as mild or moderate in most instances.

Specific research examined observations related to the investigational agent and blood pressure in participants with pre-existing heart conditions; findings from this subgroup analysis were reported. The study also assessed the investigational agent's profile in participants over 65 years of age. The study found that data from this subgroup indicated a similar profile to the overall study population.

Long-Term Outcomes

A small extension study tracked 150 participants from the main Phase III trial over one year. Data from the main trial indicated a 40% numerical difference in the rate of flare-ups compared to placebo over six months.

Research examined the investigational agent's potential for symptom changes. The observed side effect profile was documented. Research is ongoing. Findings to date describe the investigational agent's profile from clinical research.

Frequently Asked Questions (FAQ)

Common questions about Larnamin (FAQ)

Q: How quickly does Larnamin usually start to work?

A: Clinical research has examined how quickly the product may begin to show effects. For the conditions studied, some participants in clinical trials noted changes within the first two days of treatment. However, individual responses can vary, and it is important to discuss expected timelines with a healthcare provider.

Q: Can Larnamin be taken long-term?

A: Official information from clinical trials indicates that the medicine has been studied over extended periods. Researchers monitored the product's safety and effectiveness in long-term extension phases, with some participants tracked for up to one year. Decisions regarding long-term use should be reviewed with a healthcare provider.

Q: Should I take Larnamin with food, or on an empty stomach?

A: According to the official product instructions for the oral forms, it is generally recommended to take the medicine after meals. This means that the powder or tablets should be consumed following a meal or with some food. The specific administration instructions provided with the medicine should be followed.

Q: Are there any known interactions between Larnamin and supplements like Vitamin C?

A: Regulatory documents state that formal interaction studies with other medicinal products, including dietary supplements, have not been conducted. As a result, no specific interactions involving Larnamin and supplements are currently known or specified in the official regulatory labeling.

Q: Does Larnamin interact with heart medications?

A: Official drug interaction studies with other medicines, including heart medications, have not been performed. Therefore, no specific drug-to-drug interactions are listed on the regulatory label. Clinical research did, however, assess the product's profile in a subgroup of participants who had pre-existing heart conditions.

Q: Can children or teenagers use Larnamin?

A: The use of this medicine in pediatric populations, which includes children and teenagers under the age of 16, is restricted. Official guidelines advise that use in these age groups should be professionally supervised. The restriction for use in these age groups relates to safety data.

Q: Is Larnamin safe for people with kidney problems?

A: The medicine is strictly contraindicated, meaning it must not be used, if a patient has severely impaired renal (kidney) function. This severe limitation is defined by the official criteria in the product label. Individuals with kidney impairment should have their use supervised by a healthcare professional.

Q: Is Larnamin considered safe during pregnancy?

A: Official regulatory information advises that pregnant and breastfeeding individuals should only use this medicine under the guidance of a healthcare provider. The regulatory caution is in place because reliable human safety data in humans is either limited or absent.

Q: How does Larnamin compare to other medicines used for similar conditions?

A: Clinical trial data published in official sources does not include direct comparisons to other existing treatments. The research focused on assessing the product against a placebo, rather than against other active medicines used for similar conditions.

Q: Is it normal to feel slightly dizzy after taking Larnamin?

A: Official regulatory documents do not provide a structured list of common, uncommon, or rare side effects. However, all medicines require monitoring for possible adverse events that affect the central nervous system, such as dizziness. Unexpected effects should be reported to a healthcare professional.

Q: Can Larnamin affect blood pressure levels?

A: Specific safety research conducted during the clinical phases included an assessment of observations related to the investigational product and blood pressure. This study focused on participants who had pre-existing heart conditions to monitor for potential effects.

Q: Is there a best time of day to take Larnamin?

A: Regulatory instructions for the oral formulations recommend taking the dose one to two times daily. Furthermore, the instructions specify that the medicine should be consumed after meals.

Q: What happens if I forget to take a dose of Larnamin?

A: The detailed, regulatory-mandated steps for managing a missed dose cannot be established. This information is not publicly available in the official administration guidelines for the product.

Q: Can Larnamin interact with common pain relievers like ibuprofen?

A: Official drug interaction studies with other medicines, including common pain relievers, have not been formally performed. Therefore, no specific interactions between the product and pain relievers are listed on the regulatory label.

Q: Are there any major studies on Larnamin side effects?

A: Yes, safety data was a key part of the clinical development. The major Phase III trial, which involved over 1,000 participants, documented all reported adverse events and was specifically designed to assess the participant safety profile.

Q: Can Larnamin cause stomach upset or nausea?

A: While a formal, specific list of side effects is not publicly available, official administration instructions for the concentrated solution mention adjusting the infusion rate to prevent adverse gastrointestinal effects like nausea and vomiting. Any digestive upset should be discussed with a healthcare provider.

Q: Is it okay to take multivitamins while on Larnamin?

A: Formal interaction studies with other products, including multivitamins, have not been conducted. As a result, no specific interactions with multivitamins are currently known or specified in the official regulatory documentation.

Q: Is Larnamin suitable for older adults?

A: Use in older adult populations (over 65) should be professionally supervised. Specific research on this subgroup indicated that the medicine's safety profile was similar to that observed in the overall study population.

Q: Why is Larnamin sometimes used alongside other therapies?

A: Clinical trials have included research where the investigational product was used alongside other regimens, specifically light physiotherapy. This was done to assess the potential effects of a combined therapy approach in treating chronic pain conditions.

Q: Is it safe to take Larnamin while fasting?

A: The official product instructions for oral formulations generally recommend that the medicine be consumed after meals. Following this instruction would preclude taking the medicine while fasting.

Q: Are there specific food restrictions while taking Larnamin?

A: Official product warnings detail a specific substance to avoid: alcohol. Alcohol consumption must be strictly avoided because of its potential to increase the risk of liver damage and worsen the underlying condition.

Q: Is the absorption of Larnamin affected by other drugs?

A: Formal studies designed to determine if the absorption of this medicine is affected by other drugs have not been performed. Therefore, no official regulatory information is available regarding absorption-related interactions.

Q: What are the signs of an allergic reaction to Larnamin?

A: Standard regulatory guidelines state that patients should not use any medication if they have a known hypersensitivity or allergic reaction to its components. Patients are advised to seek medical attention if they experience signs of a hypersensitivity or allergic reaction.

How should Larnamin be stored and disposed of?

Larnamin (L-Ornithine L-Aspartate) must be stored and handled according to its official labeled instructions to maintain product integrity and ensure safe disposal.

Storage Requirements

  • Temperature: Store the medicine at controlled room temperature, typically not exceeding 25 C or 30 C, depending on the specific formulation license.
  • Protection: The product must be stored protected from light and moisture. Granule containers must be kept tightly closed.
  • Child Safety: Keep the medicine out of the sight and reach of children and pets.

Disposal Instructions

  • Discarding Unused Product: Any unused portion of the concentrated solution for infusion must be discarded after preparation.
  • Environmental Rules: Do not allow the product to enter drains, the sewer system, or waterways. Expired or unwanted product must be disposed of at an approved waste disposal plant, following all local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Larnamin found in:

A-Z Index: